SynAct Pharma: New Trial in Respiratory Infections - Redeye

Redeye is optimistic about the new investigator-sponsored phase II trial in respiratory infections, seeing it as improving the investment case. It represents a market with blockbuster opportunity with limited competition and a quicker way to the market.

Länk till analysen i sin helhet: https://www.redeye.se/research/1146904/synact-pharma-new-trial-in-respiratory-infections?utm_source=finwire&utm_medium=RSS